Evidence map›Paper›PMID 25285280›Full record

ArticleIndian journal of endocrinology and metabolism2014

Prevalence of dyslipidemia in adult Indian diabetic patients: A cross sectional study (SOLID).

Ambrish Mithal, Debashish Majhi, M Shunmugavelu, Pradeep G Talwarkar, Hardik Vasnawala, Ammar S Raza

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Dyslipidemia in diabetes: a population-based study in Bali.International journal of general medicine · 2019
    Article
  18. Article
  19. Article
  20. Introduction to real-world evidence studies.Perspectives in clinical research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ambrish MithalChairman, Division of Endocrinology and Diabetes, Medanta The Medicity, Gurgaon, Haryana, India.
Debashish MajhiConsultant Diabetologist and Endocrinologist, Calcutta Diabetes and Endocrine Foundation, Kolkata, West Bengal, India.
M ShunmugaveluConsultant Diabetologist, Chairman, Trichy Diabetes Speciality Centre (P) Ltd, Trichy, Tamil Nadu, India.
Pradeep G TalwarkarConsultant Diabetologist, Diabetes Clinic, Dadar, Mumbai, Maharashtra, India.
Hardik VasnawalaMedical Affairs Astra Zeneca Pharma India Ltd, Hebbal, Bangalore, Karnataka, India.
Ammar S RazaMedical Affairs Astra Zeneca Pharma India Ltd, Hebbal, Bangalore, Karnataka, India.
AstraZeneca (India) · INMedanta The Medicity · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextIndia leads the world with largest number of diabetic patients and is often referred to as the diabetes capital of the world. Diabetic dyslipidemia in India is one of the main cause for Coronary Artery Disease (CAD) mortality. Although diabetes continues to be a major lifestyle condition in India, there is a lack of studies in India on whether dyslipidemia in Indian diabetics is being adequately controlled. Our study provides critical insights into the insights into proportion of diabetes patients achieving lipid goal in India.

aimsThe primary objective of our study was to assess the control of dyslipidemia in the Indian diabetic population treated with lipid lowering drugs (LLDs), as per American Diabetes Association (ADA) 2010 guidelines. SETTINGS AND

designThe study was carried out in a real world Indian clinical setting involving 178 sites. This is a multicenter, noninterventional, and cross-sectional observational study. MATERIALS AND

methodsA total of 5400 adult subjects with established type-2 diabetes mellitus (T2DM) and dyslipidemia were recruited for the study. Patients in the study were on LLD at a stable dose for at least last 3 months before the designated study visit. Routine lipid profile tests were conducted for all patients. STATISTICAL ANALYSIS USED: Descriptive statistics was used to analyze qualitative and discrete variables. Chi-square test and t-test were conducted to assess the existence of statistically significant association between the variables.

resultsA total of 5400 patients with T2DM from 178 centers across India were recruited. Out of the total population, 56.75% (N = 3065) of them were males. Primary end-point of low-density lipoprotein cholesterol (LDL-C) level below ADA 2010 target was achieved in a total of 48.74% (N = 2632) patients. Gender was significantly associated with lipid levels and age was significantly (P < 0.05) correlated with all lipid levels. Control rates of other lipid parameters like high-density lipoprotein cholesterol, triglyceride, and total cholesterol in the study were 60.48% (N = 3236), 57.54% (N = 3107), and 92.24% (N = 4981) respectively. Among those with overt cardiovascular disease (CVD), target LDL-C level of < 70 mg/dL was achieved in 22.87% (70 out of 306) patients. The LDL-C levels of 49.03% (N = 1768) patients who were on statin therapy were within target levels, while 53.46% (N = 634) patients who were on statin and their combinations with other LLDs had their LDL-C levels within the stipulated range.

conclusionsThis study has reveled that dyslipidemia control in Indian T2DM patients is very poor with almost half of them not reaching their LDL -C goal. Dyslipidemia being one of the main risk factors for CVD in T2DM patients there is a need to treat dyslipidemia aggressively to reduce risk of future CV events.

Indexed as

CVDdiabetesdyslipidemiaLDL

Identifiers

PMID25285280
PMCPMC4171886
OpenAlexW1562467056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.